The NOPAIN for Veterans Act amends 38 U.S.C. §8125 to define “non‑opioid pain management drug or biological product” and to require the Department of Veterans Affairs to add those products to the VA national formulary and its drug standardization list. The bill ties VA inclusion to federal payment eligibility under Medicare rules and sets a short implementation window.
This matters for VA clinicians, procurement officials, and manufacturers: it creates a fast‑track pathway for certain postoperative or regional analgesics to become available to veterans, shifts how the VA evaluates new analgesic products, and raises operational and budget questions because the statute bars use of funds from the Cost of War Toxic Exposures Fund to pay for the change.
At a Glance
What It Does
The bill defines non‑opioid pain management drugs and requires the Secretary of Veterans Affairs to add those products to the VA national formulary and to the department’s drug standardization list. The add‑to‑formulary obligation is triggered when a product becomes eligible for specified Medicare payment mechanisms; VA must act within a one‑year window and complete implementation steps within 90 days of enactment.
Who It Affects
VA Pharmacy Benefits, VA medical center formularies, prescribers treating postoperative or regional pain in veterans, and manufacturers of FDA‑approved non‑opioid analgesics whose Medicare payment status will now influence VA listing decisions.
Why It Matters
The measure aligns VA procurement decisions with Medicare payment signals, potentially accelerating veteran access to new non‑opioid analgesics while concentrating budgetary and clinical assessment choices inside VA pharmacy policy. For manufacturers, Medicare payment may now create a predictable pathway to VA uptake.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a targeted definition to title 38 that covers drugs and biologicals cleared or approved by the FDA to reduce postoperative pain or to provide postsurgical or regional analgesia, provided they do not act on opioid receptors. That definition frames which products the VA must consider under the new listing rule.
VA’s obligation is outcome‑triggered: when a product becomes eligible for a specific Medicare temporary additional payment or is eligible for separate payment under a cited federal regulation, VA must place that product on its national formulary within one year and also include it on the department’s drug standardization list. Practically, that creates an external signal (Medicare payment eligibility) that compels an internal VA formulary decision rather than leaving timing solely to VA clinical review cycles.The bill also draws two operational lines.
First, it bars using the Cost of War Toxic Exposures Fund to finance the statutory changes, pushing fiscal responsibility back into VA’s regular pharmacy budgets or into appropriations. Second, it forces the Secretary to begin implementing the statutory changes within 90 days of enactment, which compresses administrative timelines for clinical evaluation, contracting, inventory, and provider guidance.Together those clauses will change how VA pharmacy committees prioritize new non‑opioid analgesics: a product’s commercial and Medicare rollout will influence VA placement, limiting the department’s discretion over the sequence and timing of clinical adoption.
That raises practical questions about prior authorization, formulary exceptions, provider education, and supply logistics that VA must resolve quickly to meet the bill’s deadlines.
The Five Things You Need to Know
The bill inserts a statutory definition: a 'non‑opioid pain management drug or biological product' is an FDA‑approved/cleared product that reduces postoperative pain or produces postsurgical or regional analgesia without acting on opioid receptors.
VA must add an eligible product to the national formulary within one year of that product becoming eligible for temporary additional Medicare payment under 42 U.S.C. §1395l(t)(16)(G) or for separate payment under 42 C.F.R. §416.174 (or successor regulation).
The bill also requires inclusion of the product on the VA drug standardization list, which determines preferred drugs across VA medical centers and can drive procurement and prescribing patterns.
The Cost of War Toxic Exposures Fund (38 U.S.C. §324) is explicitly prohibited from being used to implement these amendments.
The Secretary must implement the amendments within 90 days of the law’s enactment, creating a compressed administrative timeline.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the act as the 'NOPAIN for Veterans Act.' This is purely titular but signals congressional intent to focus on non‑opioid postoperative and regional analgesia for veterans.
New statutory definition for non‑opioid pain products
Adds a definition into 38 U.S.C. §8125 that limits the category to FDA‑approved/cleared drugs or biologics intended to reduce postoperative pain or to provide postsurgical or regional analgesia and that do not act on opioid receptors. That precise framing excludes multimodal uses or general analgesics that work via opioid pathways and creates a clear gate for what the VA must consider under the new listing requirement.
Formulary and standardization listing obligation tied to Medicare payment eligibility
Creates an affirmative duty for the Secretary to add qualifying non‑opioid products to the VA national formulary and the VA drug standardization list. The duty is triggered by external Medicare payment events—temporary additional payment under a named Medicare provision or eligibility under a specific CMS regulation—shifting part of VA’s adoption timeline from internal clinical review to federal payment status.
Technical redesignation
Redesignates the existing subsection lettering to accommodate the new definition and new duty. This is a housekeeping move but important for where the new definitions and obligations sit in statutory text and for cross‑references in VA policy documents and regulations.
Funding restriction
Prohibits use of the Cost of War Toxic Exposures Fund to implement the statutory changes. That limitation channels the financial impact into VA’s existing pharmacy budgets or appropriations rather than tapping a reserve fund tied to toxic exposure compensation.
Implementation deadline
Requires the Secretary to implement the amendments within 90 days of enactment. This imposes a short administrative deadline that will require rapid updates to VA formulary procedures, procurement planning, and clinician guidance to meet the statute’s deadlines.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Veterans undergoing surgery or regional procedures — faster access to FDA‑cleared non‑opioid postoperative and regional analgesics could reduce reliance on opioids and expand treatment options.
- VA prescribers and pain specialists — having specified non‑opioid options on the national formulary and the drug standardization list simplifies prescribing, reduces local approval barriers, and promotes uniform availability across facilities.
- Manufacturers of qualifying non‑opioid analgesics — Medicare payment eligibility now creates a predictable lever for VA formulary inclusion, improving market access and potential demand forecasts.
- VA clinical programs focused on opioid stewardship — the statutory pathway supports broader, system‑level adoption of alternatives to opioids, which helps meet stewardship and quality targets.
Who Bears the Cost
- VA Pharmacy Benefits and budget managers — adding drugs to the national formulary and standardization list shifts acquisition and inventory costs to VA’s regular budget lines, which must absorb new expenditures since the Cost of War fund is off limits.
- VA medical centers’ pharmacy and therapeutics committees — compressed timelines and external triggers will increase workload for clinical evaluations, formulary reviews, and implementation logistics.
- Taxpayers / appropriations process — absent use of the restricted fund, expanded VA drug coverage will likely increase discretionary obligations that Congress may need to fund through appropriations over time.
- Smaller pharmaceutical manufacturers that lack Medicare coverage or the resources to secure rapid CMS payment status — they may be unable to access the VA pathway, concentrating opportunities among products that already meet Medicare payment triggers.
Key Issues
The Core Tension
The central dilemma is speed versus stewardship: the bill forces faster VA access to FDA‑cleared non‑opioid analgesics by using Medicare payment as a trigger, but that expediency can outpace VA’s clinical review, budget planning, and implementation capacity—producing earlier availability at the potential cost of clinical oversight, consistent access, and fiscal control.
The bill solves access timing by tying VA action to Medicare payment eligibility, but that linkage creates several implementation questions. First, Medicare payment eligibility is a financial/coverage determination that may not align with the VA’s clinical review cycles or evidence thresholds; VA clinicians might be required to list a product before local clinical guidelines, comparative effectiveness reviews, or supply agreements are in place.
Second, the statutory definition focuses narrowly on postoperative and regional analgesia and excludes products that act on opioid receptors, but real‑world use often extends beyond those categories; the VA will need clear protocols for off‑label or broader pain indications.
Operationally, the 90‑day implementation deadline and one‑year listing window force rapid changes to procurement, contracting, and electronic health record order sets. Those compressed timelines risk rollout mistakes—insufficient provider training, stockouts, or inconsistent prior authorization rules across facilities.
The funding prohibition on the Cost of War fund deflects fiscal pressure to VA’s existing pharmacy appropriations, but the bill provides no dedicated appropriation or transition funding, raising the prospect of budgetary tradeoffs within VA programs.
Finally, relying on Medicare payment status as a trigger privileges products that can secure CMS payment quickly; that may advantage certain manufacturers and delivery settings (e.g., hospital outpatient pathways) while leaving out promising agents that lack that payment pathway. The result could be speed at the expense of comprehensiveness in available non‑opioid options.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.